FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3174552023> ?p ?o ?g. }

• W3174552023 abstract "Introduction: Mirabegron is available for treatment of storage symptoms in overactive bladder, which may be improved by β 3 -adrenoceptor-induced bladder smooth muscle relaxation. In addition to storage symptoms, lower urinary tract symptoms in men include obstructive symptoms attributed to benign prostatic hyperplasia, caused by increased prostate smooth muscle tone and prostate enlargement. In contrast to the bladder and storage symptoms, effects of mirabegron on prostate smooth muscle contraction and obstructive symptoms are poorly understood. Evidence from non-human smooth muscle suggested antagonism of α 1 -adrenoceptors as an important off-target effect of mirabegron. As α 1 -adrenergic contraction is crucial in pathophysiology and medical treatment of obstructive symptoms, we here examined effects of mirabegron on contractions of human prostate tissues and on proliferation of prostate stromal cells. Methods: Contractions were induced in an organ bath. Effects of mirabegron on proliferation, viability, and cAMP levels in cultured stromal cells were examined by EdU assays, CCK-8 assays and enzyme-linked immunosorbent assay. Results: Mirabegron in concentrations of 5 and 10 μM, but not 1 µM inhibited electric field stimulation-induced contractions of human prostate tissues. Mirabegron in concentrations of 5 and 10 µM shifted concentration response curves for noradrenaline-, methoxamine- and phenylephrine-induced contractions to the right, including recovery of contractions at high concentrations of α 1 -adrenergic agonists, increased EC 50 values, but unchanged E max values. Rightshifts of noradrenaline concentration response curves and inhibition of EFS-induced contractions were resistant to L-748,337, l -NAME, and BPIPP. 1 µM mirabegron was without effect on α 1 -adrenergic contractions. Endothelin-1- and U46619-induced contractions were not affected or only inhibited to neglectable extent. Effects of mirabegron (0.5–10 µM) on proliferation and viability of stromal cells were neglectable or small, reaching maximum decreases of 8% in proliferation assays and 17% in viability assays. Mirabegron did not induce detectable increases of cAMP levels in cultured stromal cells. Conclusion: Mirabegron inhibits neurogenic and α 1 -adrenergic human prostate smooth muscle contractions. This inhibition may be based on antagonism of α 1 -adrenoceptors by mirabegron, and does not include activation of β 3 -adrenoceptors and requires concentrations ranging 50-100fold higher than plasma concentrations reported from normal dosing. Non-adrenergic contractions and proliferation of prostate stromal cells are not inhibited by mirabegron." @default.
• W3174552023 created "2021-07-05" @default.
• W3174552023 creator A5010017816 @default.
• W3174552023 creator A5011187639 @default.
• W3174552023 creator A5020919165 @default.
• W3174552023 creator A5023326956 @default.
• W3174552023 creator A5024794927 @default.
• W3174552023 creator A5026532714 @default.
• W3174552023 creator A5066330818 @default.
• W3174552023 creator A5082326764 @default.
• W3174552023 date "2021-06-24" @default.
• W3174552023 modified "2023-09-27" @default.
• W3174552023 title "Concentration-dependent alpha1-Adrenoceptor Antagonism and Inhibition of Neurogenic Smooth Muscle Contraction by Mirabegron in the Human Prostate" @default.
• W3174552023 cites W1500193738 @default.
• W3174552023 cites W1569634341 @default.
• W3174552023 cites W1596457615 @default.
• W3174552023 cites W1787320721 @default.
• W3174552023 cites W1917215138 @default.
• W3174552023 cites W1945095845 @default.
• W3174552023 cites W1963810625 @default.
• W3174552023 cites W1972532589 @default.
• W3174552023 cites W1973183671 @default.
• W3174552023 cites W1975137665 @default.
• W3174552023 cites W1981369942 @default.
• W3174552023 cites W1985639424 @default.
• W3174552023 cites W1985689558 @default.
• W3174552023 cites W1994503497 @default.
• W3174552023 cites W1999866993 @default.
• W3174552023 cites W2013142167 @default.
• W3174552023 cites W2016155421 @default.
• W3174552023 cites W2016458036 @default.
• W3174552023 cites W2018377518 @default.
• W3174552023 cites W2033682556 @default.
• W3174552023 cites W2033901716 @default.
• W3174552023 cites W2041350627 @default.
• W3174552023 cites W2056337782 @default.
• W3174552023 cites W2066404552 @default.
• W3174552023 cites W2090588428 @default.
• W3174552023 cites W2093723585 @default.
• W3174552023 cites W2099703259 @default.
• W3174552023 cites W2106826128 @default.
• W3174552023 cites W2113748458 @default.
• W3174552023 cites W2120768446 @default.
• W3174552023 cites W2138665941 @default.
• W3174552023 cites W2161608104 @default.
• W3174552023 cites W2169016904 @default.
• W3174552023 cites W2332080456 @default.
• W3174552023 cites W2339052731 @default.
• W3174552023 cites W2467659684 @default.
• W3174552023 cites W2480003153 @default.
• W3174552023 cites W2580433920 @default.
• W3174552023 cites W2742739430 @default.
• W3174552023 cites W2747730842 @default.
• W3174552023 cites W2773037751 @default.
• W3174552023 cites W2791419854 @default.
• W3174552023 cites W2793132563 @default.
• W3174552023 cites W2795643192 @default.
• W3174552023 cites W2878801661 @default.
• W3174552023 cites W2908650010 @default.
• W3174552023 cites W2917197001 @default.
• W3174552023 cites W2921970197 @default.
• W3174552023 cites W2948156973 @default.
• W3174552023 cites W2949558713 @default.
• W3174552023 cites W2973098103 @default.
• W3174552023 cites W2984626566 @default.
• W3174552023 cites W2991502159 @default.
• W3174552023 cites W2997946065 @default.
• W3174552023 cites W3027147459 @default.
• W3174552023 cites W3091951108 @default.
• W3174552023 cites W3092086455 @default.
• W3174552023 cites W3113231186 @default.
• W3174552023 cites W3120573389 @default.
• W3174552023 cites W3135862631 @default.
• W3174552023 cites W50593741 @default.
• W3174552023 doi "https://doi.org/10.3389/fphar.2021.666047" @default.
• W3174552023 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8264149" @default.
• W3174552023 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34248624" @default.
• W3174552023 hasPublicationYear "2021" @default.
• W3174552023 type Work @default.
• W3174552023 sameAs 3174552023 @default.
• W3174552023 citedByCount "6" @default.
• W3174552023 countsByYear W31745520232022 @default.
• W3174552023 countsByYear W31745520232023 @default.
• W3174552023 crossrefType "journal-article" @default.
• W3174552023 hasAuthorship W3174552023A5010017816 @default.
• W3174552023 hasAuthorship W3174552023A5011187639 @default.
• W3174552023 hasAuthorship W3174552023A5020919165 @default.
• W3174552023 hasAuthorship W3174552023A5023326956 @default.
• W3174552023 hasAuthorship W3174552023A5024794927 @default.
• W3174552023 hasAuthorship W3174552023A5026532714 @default.
• W3174552023 hasAuthorship W3174552023A5066330818 @default.
• W3174552023 hasAuthorship W3174552023A5082326764 @default.
• W3174552023 hasBestOaLocation W31745520231 @default.
• W3174552023 hasConcept C121608353 @default.
• W3174552023 hasConcept C126322002 @default.
• W3174552023 hasConcept C126894567 @default.
• W3174552023 hasConcept C134018914 @default.
• W3174552023 hasConcept C142724271 @default.
• W3174552023 hasConcept C163415756 @default.
• W3174552023 hasConcept C170493617 @default.

• next